ProShare Advisors LLC Has $871,000 Holdings in Glaukos Co. (NYSE:GKOS)

ProShare Advisors LLC trimmed its position in shares of Glaukos Co. (NYSE:GKOS) by 24.7% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 7,362 shares of the medical instruments supplier’s stock after selling 2,418 shares during the quarter. ProShare Advisors LLC’s holdings in Glaukos were worth $871,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Caldwell Sutter Capital Inc. grew its position in Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after acquiring an additional 1,465 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Glaukos by 68.8% in the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Glaukos in the second quarter valued at $187,000. Brighton Jones LLC bought a new position in shares of Glaukos in the second quarter valued at about $208,000. Finally, LVW Advisors LLC acquired a new stake in Glaukos in the 2nd quarter valued at about $213,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $128.29 on Friday. The firm’s 50 day simple moving average is $125.39 and its 200 day simple moving average is $112.95. Glaukos Co. has a fifty-two week low of $59.22 and a fifty-two week high of $136.60. The company has a market capitalization of $6.46 billion, a price-to-earnings ratio of -44.55 and a beta of 1.03. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. During the same period last year, the business posted ($0.55) earnings per share. The business’s revenue for the quarter was up 19.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Glaukos Co. will post -2.18 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on GKOS shares. Morgan Stanley upped their target price on shares of Glaukos from $100.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Piper Sandler increased their price objective on Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Truist Financial restated a “buy” rating and set a $145.00 target price (up previously from $141.00) on shares of Glaukos in a research report on Thursday, August 1st. Wells Fargo & Company raised their price target on Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus boosted their price objective on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.82.

Insiders Place Their Bets

In other news, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares in the company, valued at $4,225,345.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 2,250 shares of the firm’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $121.39, for a total transaction of $273,127.50. Following the sale, the chief operating officer now owns 101,845 shares in the company, valued at $12,362,964.55. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,500 shares of company stock worth $5,099,000. Corporate insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.